Cryosite Ltd - Asset Resilience Ratio
Cryosite Ltd (CTE) has an Asset Resilience Ratio of 20.55% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cryosite Ltd (CTE) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Cryosite Ltd's Asset Resilience Ratio has changed over time. See CTE book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cryosite Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CTE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$4.00 Million | 20.55% |
| Total Liquid Assets | AU$4.00 Million | 20.55% |
Asset Resilience Insights
- Good Liquidity Position: Cryosite Ltd maintains a healthy 20.55% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cryosite Ltd Industry Peers by Asset Resilience Ratio
Compare Cryosite Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 57.28% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Cryosite Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Cryosite Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 20.55% | AU$4.00 Million ≈ $2.83 Million |
AU$19.46 Million ≈ $13.77 Million |
+0.26pp |
| 2024-06-30 | 20.29% | AU$4.00 Million ≈ $2.83 Million |
AU$19.71 Million ≈ $13.95 Million |
-9.43pp |
| 2023-06-30 | 29.72% | AU$6.73 Million ≈ $4.76 Million |
AU$22.65 Million ≈ $16.02 Million |
+4.88pp |
| 2022-06-30 | 24.84% | AU$5.34 Million ≈ $3.78 Million |
AU$21.50 Million ≈ $15.21 Million |
+7.19pp |
| 2021-06-30 | 17.65% | AU$3.88 Million ≈ $2.75 Million |
AU$21.99 Million ≈ $15.56 Million |
+0.36pp |
| 2020-06-30 | 17.28% | AU$4.06 Million ≈ $2.87 Million |
AU$23.50 Million ≈ $16.63 Million |
-1.03pp |
| 2019-06-30 | 18.31% | AU$4.24 Million ≈ $3.00 Million |
AU$23.17 Million ≈ $16.40 Million |
-42.23pp |
| 2018-06-30 | 60.54% | AU$4.69 Million ≈ $3.32 Million |
AU$7.74 Million ≈ $5.48 Million |
+8.75pp |
| 2017-06-30 | 51.79% | AU$5.09 Million ≈ $3.60 Million |
AU$9.83 Million ≈ $6.95 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.66 Million ≈ $6.83 Million |
-- |
About Cryosite Ltd
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more